The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1527 - 1539
In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events...
MEDICINE, GENERAL & INTERNAL | EVENTS | REDUCTION | STATIN THERAPY | REDUCING LIPIDS | PCSK9 | GENETIC-VARIANTS | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Male | Injections, Subcutaneous - adverse effects | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Lipids - blood | Treatment Failure | Antibodies - blood | Cholesterol, LDL - blood | Female | Antibodies, Monoclonal, Humanized - immunology | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Immunoglobulins | Stroke | Risk groups | Clinical trials | Cardiovascular disease | Lipids | Subtilisin | Angina | Low density lipoprotein | Manuscripts | Cholesterol | Disease prevention | Kexin | Monoclonal antibodies | Cardiovascular diseases | Life Sciences | Human health and pathology
MEDICINE, GENERAL & INTERNAL | EVENTS | REDUCTION | STATIN THERAPY | REDUCING LIPIDS | PCSK9 | GENETIC-VARIANTS | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Male | Injections, Subcutaneous - adverse effects | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Lipids - blood | Treatment Failure | Antibodies - blood | Cholesterol, LDL - blood | Female | Antibodies, Monoclonal, Humanized - immunology | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Immunoglobulins | Stroke | Risk groups | Clinical trials | Cardiovascular disease | Lipids | Subtilisin | Angina | Low density lipoprotein | Manuscripts | Cholesterol | Disease prevention | Kexin | Monoclonal antibodies | Cardiovascular diseases | Life Sciences | Human health and pathology
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2012, Volume 367, Issue 4, pp. 319 - 328
In this study with a 2-by-2 factorial design, patients with cardiovascular risk factors and dysglycemia or type 2 diabetes received insulin glargine or...
DIABETES-MELLITUS | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | THERAPY | GLARGINE | GLUCOSE CONTROL | DISEASE | RISK | PEOPLE | ENDOTHELIAL FUNCTION | BETA-CELL FUNCTION | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Male | Incidence | Glucose Intolerance - drug therapy | Cardiovascular Diseases - epidemiology | Female | Drug Therapy, Combination | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Fasting | Blood Glucose - analysis | Double-Blind Method | Proportional Hazards Models | Hospitalization | Glucose Intolerance - complications | Insulin, Long-Acting - adverse effects | Insulin Glargine | Insulin, Long-Acting - therapeutic use | Intention to Treat Analysis | Triglycerides - blood | Fatty Acids, Omega-3 - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Insulin glargine | Patient outcomes | Causes of | Cardiovascular diseases | Risk factors | Myocardial infarction | Fees & charges | Cerebral infarction | Medical research | Stroke | Heart attacks | Statistical analysis | Diabetes mellitus | Glucose | Hypoglycemia | Fatty acids | Insulin | Glucose tolerance | Insulin resistance | Microvasculature | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Cardiovascular Diseases | Insulin, Long-Acting | Blood Glucose | Triglycerides | Glucose Intolerance | Cholesterol | Life Sciences | Hypoglycemic Agents | Diabetes Mellitus, Type 2 | Fatty Acids, Omega-3 | Medical and Health Sciences | Medicin och hälsovetenskap
DIABETES-MELLITUS | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | THERAPY | GLARGINE | GLUCOSE CONTROL | DISEASE | RISK | PEOPLE | ENDOTHELIAL FUNCTION | BETA-CELL FUNCTION | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Cholesterol - blood | Humans | Middle Aged | Male | Incidence | Glucose Intolerance - drug therapy | Cardiovascular Diseases - epidemiology | Female | Drug Therapy, Combination | Hypoglycemia - chemically induced | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Fasting | Blood Glucose - analysis | Double-Blind Method | Proportional Hazards Models | Hospitalization | Glucose Intolerance - complications | Insulin, Long-Acting - adverse effects | Insulin Glargine | Insulin, Long-Acting - therapeutic use | Intention to Treat Analysis | Triglycerides - blood | Fatty Acids, Omega-3 - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Insulin glargine | Patient outcomes | Causes of | Cardiovascular diseases | Risk factors | Myocardial infarction | Fees & charges | Cerebral infarction | Medical research | Stroke | Heart attacks | Statistical analysis | Diabetes mellitus | Glucose | Hypoglycemia | Fatty acids | Insulin | Glucose tolerance | Insulin resistance | Microvasculature | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Cardiovascular Diseases | Insulin, Long-Acting | Blood Glucose | Triglycerides | Glucose Intolerance | Cholesterol | Life Sciences | Hypoglycemic Agents | Diabetes Mellitus, Type 2 | Fatty Acids, Omega-3 | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article